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Abstract  
Purpose of review: To review the role of pre-biopsy multi-parametric MRI in 
biopsy-naïve men for the detection of clinically significant prostate cancer.  
 
Recent findings: Recent Level 1 evidence shows that multi-parametric MRI has 
high sensitivity and negative predictive value for the detection of clinically 
significant prostate cancer in biopsy-naïve men. Concurrent developments include 
important work in the standardization of MRI-reporting. The low specificity and 
positive predictive value of MRI means that biopsy is still necessary following MRI. 
MRI-targeted prostate biopsy has emerged as an alternative diagnostic test to trans-
rectal ultrasound guided prostate biopsy, though its exact role in biopsy naïve men 
and the optimal technique remain to be defined.  
 
Summary: There is the potential for MRI to be used as a triage test to allow a 
proportion of men to avoid biopsy and remain on PSA surveillance. MRI-suspicious 
areas can be sampled more intensively using MRI-targeted biopsy that can be 
carried out in a variety of ways. Future work should focus on the cost-effectiveness 
of introducing a pre-biopsy MRI pathway in biopsy naïve men and addressing the 
training needs for such a change.   
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Introduction 
Prostate cancer is the second commonest cancer in men in the world[1]. 
Prostate specific antigen (PSA) testing forms the basis for screening men at risk of 
prostate cancer for further investigation. The benefit of PSA screening has been 
widely debated as there is a fine margin between offering a survival benefit and 
inflicting harm from overtreatment [2, 3]. The United States Preventive Services 
Task Force (USPSTF) recommended against prostate cancer screening and gave it a 
grade D recommendation [4]. There is therefore a need to optimize diagnostic 
strategies that identify men with clinically significant cancer who will benefit from 
treatment.  
Advances in prostate MRI tend to suggest that it should have a key role in the 
prostate cancer management algorithm, particularly before a biopsy is done. Recent 
studies such as the PROMIS Trial raise an important question as to whether pre-
biopsy multi-parametric MRI should have a routine role in biopsy naïve men for the 
identification of prostate cancer[5].  
 
 
 
 
 
 
 
 
The role of MRI in the current prostate cancer diagnostic pathway for biopsy 
naïve men 
Many current practice guidelines, such as the European Association of 
Urology, the National Institute of Health Care and Excellence (NICE) and the 
American Urology Association guidelines endorse a diagnostic pathway that 
includes a digital rectal examination (DRE) and PSA typically followed by a 10-12 
core transrectal-ultrasound guided (TRUS) guided prostate biopsy if either of the 
two is abnormal.[6] [7] [8].   
The use of pre-biopsy MRI in the routine prostate cancer guidelines appears 
to be lagging behind adoption of the technology in many centers. The National 
Comprehensive Cancer Network (NCCN) in their 2016 guidelines state that “MRI is 
not recommended routinely prior to initial prostate biopsy” however they do 
acknowledge that MRI/US fusion targeted biopsy may increase the detection of 
clinically significant higher risk disease while lowering the detection of lower risk 
disease[9]. However, in order to recommend MRI routinely both diagnostic accuracy 
and cost-effectiveness should be clearly demonstrated.  The UK NICE guidelines on 
prostate cancer: diagnosis and management will be updated in mid 2017 and it is 
likely that guidelines on the use of pre-biopsy MRI in biopsy naïve men will be 
featured especially in light of the recent publication of the PROMIS Trial [5, 10]. 
 
 
 
 
 Problems with the existing diagnostic pathway that MRI may potentially solve 
The current screening pathway of DRE, PSA then TRUS biopsy has its 
limitations.  The European Randomized Screen for Prostate (ERSPC) Trial found that 
75.9% of men with a PSA greater than 3.0ng/ml that went on to have a TRUS biopsy 
were negative for cancer. They also found a cumulative risk of 12% of at least 1 false 
positive PSA after 3 rounds of PSA testing every 4 years. The Rotterdam Centre had 
a rate of overdiagnosis as high as 66% [3].  
The Standard systematic 12 core TRUS biopsy has a sensitivity ranging from 
45-75% for clinically significant prostate cancer[11, 12] [13]. Transperineal 
Template mapping biopsy (TTMB) has sought to improve on these sensitivities by 
taking more cores and sampling the anterior and midline prostate which can be 
difficult to reach via the trans rectal route. It also reduces the risks of sepsis 
associated with the trans rectal route. However TTMB usually requires dedicated 
equipment, expertise, spinal or general anesthesia and can result in greater 
overdetection of clinically insignificant cancer [14]. 
Adverse events associated with the TRUS biopsy procedure are well 
documented. Hematuria/hematospermia rates are between 20-50%. Fever post 
biopsy is between 3.5-4.2% [3]. More serious complications were found in 
68/100,000 biopsies i.e. infections, bleeding and urinary difficulties [2]. 
Hospitalization post biopsy was found to be 4% [15]. Of concern was the recent 
finding that a man with a negative TRUS biopsy had a risk of death from prostate 
cancer of 5.2%, which is greater than the lifetime risk of prostate cancer death for 
the average man [16, 17]. 
By performing a pre-TRUS biopsy mpMRI it may be possible to: 
Reduce the number of biopsies performed, thereby, reducing over diagnosis, false 
positive rates and adverse events associated with biopsy. It may also be possible to 
target suspicious lesions more accurately to improve sensitivity and specificity for 
the detection of clinically significant cancer [18]. 
 
Improvements in MRI 
When MRI was first considered for prostate cancer diagnosis it lacked 
sensitivity and specificity when compared to TRUS biopsy as it was limited to the 
use of anatomic T2 weighted MRI sequences. The rapid optimization of MRI 
technology has led to functional imaging using diffusion-weighted, dynamic 
contrast-enhanced and spectroscopic imaging. Combining these functional 
techniques with the traditional (T1/T2) techniques (parameters) resulted in a multi 
parametric MRI (mpMRI) which has led to improved diagnostic performance for the 
detection of high grade lesions [19].  
 The European Society of Urogenital Radiology and other expert Uro-
radiology groups have led attempts at standardizing the reporting of prostate 
mpMRI [20]. The Prostate Imaging Reporting And Data System (PIRADS) and Likert 
scores for ascribing risk of clinically significant prostate cancer represent significant 
steps forward in increasing the applicability of the prostate MRI in non-expert 
centers [21]. It is clear from the experience of multi-centre clinical trials in Prostate 
MRI such as PROMIS and PRECISION (NCT02380027), that optimization of the 
conduct of the MRI and reporting experience of the radiologists are key factors in 
determining the performance of the technology.  
The Prostate MR Imaging study (PROMIS) provides level 1 evidence for the 
contemporary diagnostic performance of mpMRI validated against TTPB in biopsy 
naïve men [5]. 576 men underwent 1.5T mpMRI with a reference standard of TTPB. 
Sensitivity was 93%, specificity 41%, positive predictive value 51% and negative 
predictive value 89% for the detection of clinically significant cancer (Gleason score 
≥4 + 3 or a maximum cancer core length 6 mm or longer). MpMRI compared 
favourably to TRUS biopsy with regards to sensitivity and negative predictive value, 
though the specificity and positive predictive value of TRUS biopsy were superior. 
The implications of these results will be discussed in the appropriate sections below 
where the potential role of mpMRI in the diagnostic pathway for prostate cancer 
will be discussed (Table 1). 
 
MpMRI as a triage test 
By doing a pre biopsy mpMRI it may be possible to exclude men at low risk of 
having clinically significant cancer from going on to having a biopsy. To do this, 
mpMRI needs to have a high negative predictive value for the detection of clinically 
significant cancer. The negative predictive value of mpMRI for clinically significant 
prostate cancer varies widely in the available literature. This may depend on the 
techniques, interpreters or the definition of clinically significant prostate cancer 
used. A literature review by Futterer et al  has found a range from 63-98%[22].  
The Prostate MR Imaging Study (PROMIS) trial is one of the largest 
prospective level 1b evidence trials to add evidence to this debate[5]. Several of the 
centers involved in PROMIS were not specialized academic centers and MRI was 
carried out on 1.5T machines rather than 3T to show the performance of the test in 
scanners with coil strengths that are more readily accessible to most centers. The 
landmark finding was that of a negative predictive value of 89% for the detection of 
clinically significant prostate cancer (Gleason score ≥4 + 3 or a maximum cancer 
core length 6 mm or longer.) The study design ensured the conduct and reporting of 
MRIs was tightly controlled and this standardization will need to be replicated in 
other non-specialist centers if these results wish to be replicated.  
However, according to the secondary definition  of clinically significant 
prostate cancer (Gleason score ≥3 + 4 or a maximum cancer core length 4mm) the 
negative predictive value was 72%. For some practitioners, missing 28% of 
clinically significant cancer according to this less stringent definition may seem high. 
One should appreciate, however, that men with negative MRIs are not discharged 
without follow up but continue on PSA surveillance. Further, the results must be 
appreciated in the context of what men would otherwise get. If it was a TRUS biopsy, 
the negative predictive value was still lower than MRI in this study. At the very least, 
the results of this trial allow an informed discussion with a man who has a negative 
MRI to consider whether he wishes to avoid a biopsy and embark on PSA 
surveillance. 
Before routinely adapting pre-biopsy MRI in all biopsy naïve men, this 
practice would need to be proven cost effective. Although cost effectiveness in the 
prior negative biopsy group has been demonstrated, we await robust cost-
effectiveness analysis in the biopsy naïve group [23]. 
 
 
MpMRI as an additional test to guide MRI-targeted biopsy 
If a suspicious lesion has been identified on an MRI, this can be sampled by a 
targeted biopsy. Currently the three ways to do so are MRI visual estimation/ 
cognitive registration, MRI-ultrasound fusion and the In-bore MRI guided biopsy. 
Cognitive biopsies rely on the operator to review the images and make an effort to 
deliberately sample the suspicious area using TRUS guidance. MRI-Fusion biopsies 
use software to co-register the MRI prostate contours and lesion location onto the 
realtime ultrasound. In bore MRI-targeted biopsies are done within an MRI scanner, 
using MRI compatible biopsy equipment.  
There are few original studies in MRI-targeted biopsies that are 
appropriately powered to be able to tell if there is a difference between clinically 
significant cancer detection by MRI-targeted biopsy and TRUS-biopsy.  An ongoing 
prospective randomized trial, PRECISION (NCT02380027), will attempt to address 
this, comparing CDRs of MRI-targeted prostate biopsy to TRUS biopsy in 470 biopsy 
naïve men. There are however many smaller studies already published from 
specialist centers which have found significant improvements in CDRs, particularly 
with regards to clinically significant cancer, and lower detection rates of clinically 
insignificant cancer rates using MRI guided techniques [24-29]. A metanalysis by 
Schoots found a higher detection rate of clinically significant cancer and a lower 
detection rate of clinically insignificant cancer with MRI targeted biopsy techniques. 
Significant improvement in detection was particularly seen in a subset of men with a 
prior negative biopsy.  [30]. It has not been established whether one particular 
technique for MRI-targeted biopsy is superior to another. The PROFUS trial, a 
prospective blinded comparison of the CDRs of cognition TRUS biopsy and 
MRI/TRUS fusion showed no statistically significant difference in CDRs between the 
two types of MRI-targeted biopsy registration techniques however there was a 
trend towards improved CDRs in their subgroup analysis. The authors suggest that 
these results may be due to the fact that there were only 125 patients in the 
study[31].  
Data from some of the key recent studies in biopsy naïve men evaluating MRI 
targeted biopsy are summarized in Table 2.  Panebianco et al carried out a 
randomized controlled trial in 1140 men. In Group A, all men underwent TRUS 
biopsy. In group B, all men underwent pre-biopsy MRI, TRUS biopsy and in addition, 
MRI-targeted cognitive biopsy in the presence of a suspicious lesion. They found 
higher CDRs in Group B (73%) versus group A (38%)[32]. Though other studies 
follow a similar trend, the wide differences seen in this well powered study have not 
been seen in other studies.   
A randomized controlled trial in 130 men by Tonttila et al compared a group 
of men undergoing standard TRUS biopsy to a group of men with a pre-biopsy MRI 
then standard TRUS + MRI/Fusion biopsies of MRI suspicious lesions where 
present. Cancer detection was 34/53 (64%) in the MRI arm and 34/60 (57%) in the 
TRUS biopsy arm. Significant cancer detection was 29/53 (55%) and 27/60 (45%), 
respectively.  There were no statistically significant differences identified, though 
the comparison was underpowered.  [28].  
 Siddiqui et al reported a prospective paired cohort study in 1003 men 
undergoing pre-biopsy MRI, TRUS biopsy and MRI-targeted biopsy. 196 men were 
biopsy naïve and the remaining had a prior negative biopsy. Though there was no 
difference in overall CDRs between TRUS biopsy and targeted MRI/fusion, 30% 
more high-grade cancer was diagnosed with targeted biopsy than TRUS biopsy 
cores (173 cases versus 122 cases). [27]. This study highlights one of the key 
advantages of the MRI-influenced pathway – the ability to identify significant cancer 
whilst avoiding the diagnosis of clinically insignificant cancer.  
Another important consideration is whether an MRI-targeted only biopsy 
approach (i.e. no additional systematic cores) can be taken or whether additional 
systematic cores need to be taken from MRI-negative areas. Baco et al performed a 
randomized control trial on 175 biopsy naïve men comparing a standard TRUS 
biopsy and 2 core TRUS targeted biopsy of DRE or TRUS suspicious lesion versus a 
2-core MRI/TRUS fusion biopsy and standard TRUS biopsy. They found no 
significant difference in overall cancer detection rates (54% vs 59%; p value 0.4) or 
clinically significant prostate cancer detection rates (49% vs 44%; p value 0.5) 
between the two groups. Interestingly, they found no statistically significant 
difference in the clinically significant CDR between a 2 core MRI/TRUS fusion biopsy 
vs standard biopsy (38% vs 49%; p value 0.2). This tends to suggest a targeted 2 
core approach may be sufficient[33]. 
Urologists should carefully consider the balance between biopsy core 
number, clinically significant and clinically insignificant disease detection and not 
always assume taking more biopsies is the best strategy. We should consider that 
we are in a resource-limited environment and an MRI-targeted only approach, 
which would result in fewer biopsies and fewer men diagnosed with insignificant 
cancer will have health economic and service delivery advantages.  
Though equipment for fusion and in-bore MRI techniques may be costly, this may be 
balanced out by costs saved if fewer men are biopsied and fewer biopsy cores per 
patient are taken. Issues on training non-specialist centers must also be 
considered[34]. 
 
CONCLUSION 
There have been recent notable developments in mpMRI technology, conduct 
and reporting to improve the use of MRI in prostate cancer management.  These 
have resulted in clear improvements in the performance of pre-biopsy mpMRI. 
Level 1b evidence is now available demonstrating good performance of mpMRI in 
biopsy-naïve men in ruling out high grade prostate cancer and support the 
possibility of its use as a triage test for deciding which men may be able to avoid a 
biopsy. Some evidence also exists supporting the role of mpMRI-targeted biopsy as 
an adjunct or replacement test to TRUS-biopsy, though questions remain on training 
and implementation practicalities. We also await robust cost-effectiveness data to 
support routine use of a pre-biopsy MRI-influenced diagnostic pathway. What is 
certain is that pre-biopsy mpMRI will play an increasingly important role in biopsy 
naïve men in years to come. 
 
  
Key points 
 Level 1 evidence shows that pre-biopsy multiparametric MRI has a high 
sensitivity and negative predictive value for the detection of clinically 
significant prostate cancer in biopsy naïve men.  
 Prostate MRI may be able to be used as a triage test to allow a proportion of 
men to avoid biopsy and remain on PSA surveillance 
 The low specificity and positive predictive value of MRI means that prostate 
biopsy is still necessary. MRI-targeted biopsy appears to be a reasonable 
alternative to standard 12-core transrectal ultrasound guided prostate 
biopsy though the optimal technique and its exact role in biopsy naïve men 
remains to be established  
 Analyses showing cost-effectiveness of an MRI-driven diagnostic pathway in 
biopsy naïve men are awaited 
  
Tables 
 
Table 1: The potential roles for mpMRI in diagnosing prostate cancer in biopsy-
naïve men (original table): 
1. After Digital rectal examination and Prostate specific antigen testing as a 
triage test to decide on which men can avoid biopsy and which need to go 
onto biopsy.  
2. After Digital rectal examination and Prostate specific antigen testing as an 
additional test to guide MRI-targeted biopsy, whether cognition, fusion or in-
bore MRI guided. 
 
  
  
 
 
 
 
 
 
 
Legend: (SB: Standard TRUS Biopsy. Fusion: MRI/TRUS fusion. MRCB: MRI-targeted cognitive biopsy. CDRs: Cancer detection 
rates) 
 
Table 2: A summary of the key recent studies evaluating MRI-targeted prostate biopsy in biopsy naïve men (original table) 
 
 
Study (year) Study Design Intervention(s) Sample size Population  Overall cancer 
detection 
Significant cancer 
detection 
Conclusions 
Panebianco 
2015[32] 
RCT Group A: SB 
Group B: MRI+ MRI-
targeted & SB 
1140 Biopsy naive Group A: 215/570 
(37%) 
 
Group B: 417/570 
(73%) 
Not specified The CDRs of prostate cancer is 
higher among those randomized 
toMRI then SB  with targeted 
cores vs SB alone 
Tonttila 2016[28] RCT 
 
Control: SB 
Intervention: 
MRI+SB+ fusion 
130 Biopsy naive Control: 34/60 (57%) 
Intervention: 34/53 
(64%) 
Control: 27/60 
(45%) 
Intervention: 
29/53 (55%)  
Fusion did not improve CDRs 
when compared to SB alone 
Pokorny 2014[24] 
 
 
Prospective 
cohort study 
Group A: MRI + SB 
Group B: MRI + SB 
+MRCB 
223 
 
Biopsy naive SB:126/223 (67%) 
MRCB: 99/142 (70%) 
 
SB: 79/126 (63%) 
Group B:Int/high 
risk 93/99 (94%) 
MRI/MRGB reduces the 
detection of low risk cancer and 
improves  intermediate and high 
risk cancer detection rate  
Siddiqui 2015[27] 
 
 
 
Prospective 
cohort study 
MRI+ fusion + SB  1003 
(196 Biopsy 
naïve) 
Mixed Fusion: 461/1003 
(46%) 
SB: 469/1003 (47%) 
Fusion: 173/461 
(38%) 
SB: 122/469 (26%) 
Fusion biopsy associated with 
increased CDRs of high risk 
prostate cancer and decreased  
detection of low risk prostate 
cancer but no difference in 
overall CDRs 
Porpiglia 
2016[29] 
RCT Group A: MRI + SB or 
fusion  
Group B: SB 
212 
 
Biopsy naive 
 
Group A: 54/107 
(50.5%) 
Group B: 31/105 
(29.5%) 
 
 
Not specified Pathway which incorporates MRI 
has a higher CDR for prostate 
cancer when compared to the 
pathway without MRI 
Baco 2016[33] RCT Control: SB+ 
DRE/TRUS targeted 
suspicious lesions 
Intervention: SB+ 2 
core fusion 
175 Biopsy Naive Control: 48/89 (54%) 
Intervention: 51/86 
(59%) 
 
 
Control: 44/89 
(49%) 
Intervention: 
38/86 (44%) 
 
No difference was found in 
overall CDRs or clinically 
significant prostate CDRs 
between SB and fusion. A 2-core 
targetd fusion biopsy approach 
was equivalent to SB 
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